1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €11.78 (+168.95%). The median is €10.76 (+145.66%).
| Buy |
14 |
| Hold |
19 |
| Sell |
4 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Mar 2025 | |
|---|---|---|
| Revenue | 35.78M | - |
| Gross profit | 24.47M | - |
| Net profit | -26.87M | - |
| EBITDA | -7.1M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €41.89M |
Number of shares | 9.79M |
52-week high/low | €24.62 - €2.75 |
| Dividends | No |
Beta | 0.37 |
P/E ratio | -0.20 |
PEG ratio | 0.00 |
P/B ratio | -1.53 |
P/S ratio | 0.58 |
Company profile
| Name | Bluebird Bio Aktie |
| CEO | Andrew Obenshain |
| Employees | 248 |
Discover assets
Shareholders of Bluebird Bio Aktie also invest in the following assets
